Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat.
Experimental autoimmune neuritis (EAN) is an animal model for Guillain-Barré syndrome (GBS). Intravenous immunoglobulins (IVIg) are an effective treatment for GBS, but their mechanism of action is not well understood. Here we tested whether IVIg treatment, a potent modulator of proinflammatory assaults, reduces inflammation in EAN. The evaluation of IVIg treatment failed to demonstrate a salutary effect in different models of EAN. IVIg appears not to suppress the acute inflammatory insult on the peripheral nerve, but may have beneficial long-term effects not looked for in the present investigation.
Enders
U
U
Department of Neurology, Julius-Maximilians Universität, Würzburg, Germany.
Toyka
K V
KV
Hartung
H P
HP
Gold
R
R
D000818:Animals; D005260:Female; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D009444:Neuritis, Autoimmune, Experimental / Q000628:therapy*; D011129:Polyradiculoneuropathy / Q000628:therapy; D051381:Rats; D011917:Rats, Inbred Lew
D016756:Immunoglobulins, Intravenous